Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The liver is a vital organ that plays a crucial role in the physiological operation of the human body. The liver controls the body's detoxification processes as well as the storage and breakdown of red blood cells, plasma protein and hormone production, and red blood cell destruction; therefore, it is vulnerable to their harmful effects, making it more prone to illness. The most frequent complications of chronic liver conditions include cirrhosis, fatty liver, liver fibrosis, hepatitis, and illnesses brought on by alcohol and drugs. Hepatic fibrosis involves the activation of hepatic stellate cells to cause persistent liver damage through the accumulation of cytosolic matrix proteins. The purpose of this review is to educate a concise discussion of the epidemiology of chronic liver disease, the pathogenesis and pathophysiology of liver fibrosis, the symptoms of liver fibrosis progression and regression, the clinical evaluation of liver fibrosis and the research into nanotechnology-based synthetic and herbal treatments for the liver fibrosis is summarized in this article. The herbal remedies summarized in this review article include epigallocathechin-3-gallate, silymarin, oxymatrine, curcumin, tetrandrine, glycyrrhetinic acid, salvianolic acid, plumbagin, Georgi, astragalosides, hawthorn extract, and andrographolides.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10057127PMC
http://dx.doi.org/10.3390/molecules28062811DOI Listing

Publication Analysis

Top Keywords

liver fibrosis
24
liver
12
red blood
8
chronic liver
8
fibrosis
7
understanding potential
4
potential role
4
role nanotechnology
4
nanotechnology liver
4
fibrosis paradigm
4

Similar Publications

Simple scoring model for predicting overt hepatic encephalopathy in geriatric cirrhosis: A multicenter retrospective cohort study.

Metab Brain Dis

September 2025

Department of Gastroenterology/Internal Medicine, Graduate School of Medicine, Gifu University, Gifu, 1-1 Yanagido, 501-1194, Japan.

Identifying the risk of overt hepatic encephalopathy (OHE) in geriatric patients with cirrhosis remains challenging. This study aimed to investigate the independent factors for OHE development in geriatric cirrhosis and to establish a simple scoring model to identify individuals at risk for OHE. We conducted a retrospective review of geriatric patients with cirrhosis aged ≥ 80 years who were admitted between April 2006 and November 2022.

View Article and Find Full Text PDF

The treatment of metabolic dysfunction-associated steatotic liver disease involves physical activity, weight loss, and management of comorbidities (diabetes, hypertension, dyslipidemia). In 2024, the American Food and Drug Administration provisionally approved resmetirom for metabolic dysfunction-associated steatohepatitis. Other promising molecules are being evaluated (glucagon-like peptide 1 receptor agonists, fibroblast growth factor 21 agonist).

View Article and Find Full Text PDF

Over the past few decades, liver disease has emerged as one of the leading causes of death worldwide. Liver injury is frequently associated with infections, alcohol consumption, or obesity, which trigger hepatic inflammation and ultimately lead to progressive fibrosis and carcinoma. Although various cell populations contribute to inflammatory and fibrogenic processes in the liver, macrophages serve as a pivotal mediator.

View Article and Find Full Text PDF

Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a rising health issue linked to poor diet and gut microbiota dysbiosis. The Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diet, high in polyphenols and anti-inflammatory nutrients, may help protect against MASLD. This study examined how adherence to the MIND diet relates to MASLD severity, focusing on hepatic steatosis, fibrosis, insulin resistance, inflammation, and gut microbiota diversity.

View Article and Find Full Text PDF

Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as a major contributor to systemic metabolic dysfunction and is increasingly recognized as a risk enhancer for both cardiovascular disease (CVD) and chronic kidney disease (CKD). This review explores the complex interconnections between MASLD, CVD, and CKD, with emphasis on shared pathophysiological mechanisms and the clinical implications for risk assessment and management. We describe the crosstalk among the liver, heart, and kidneys, focusing on insulin resistance, chronic inflammation, and progressive fibrosis as key mediators.

View Article and Find Full Text PDF